A Liquid Biopsy is a less intrusive alternative to surgical biopsies that makes it possible to find a tumour with just a small blood sample. The most effective therapy for a patient can be determined by looking for DNA traces of the malignancy in the patient's blood. Non-small cell lung cancer (NSCLC) is diagnosed via liquid biopsies, which are also used to screen for NSCLC and as a companion diagnosis for other malignancies include gastrointestinal, colorectal, breast, prostate, and ovarian cancer. The main drivers of Liquid Biopsy Market expansion include liquid biopsy's excellent efficacy and low cost compared to other diagnostic techniques. The FDA's (U.S. Food and Drug Administration) expedited approval process for non-invasive cancer detection tests will continue to open up new business prospects.
Humanity has been impacted by cancer for decades, and despite the development of better care and treatment, the number of cases is still rising. The World Health Organization (WHO) estimated that cancer-related fatalities will account for roughly 10 million deaths in 2020. This astounding increase in numbers highlights the requirement for precise and practical cancer testing tools for early detection. Governments in a number of countries with high cancer incidence rates have promised to support cancer research by allocating enough funding that can lead to better results. For instance, the National Cancer Institute will get US$119 million from the federal government for the fiscal year 2021, according to the National Institute of Health (NIH).
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2023/02/global-liquid-biopsy-market-is.html
